SHIRE, U.S.' NEW RIVER TO DEVELOP HYPERACTIVITY TREATMENT

Shire Pharmaceuticals Group said it signed an agreement to globally develop and commercialize a new attention-deficit/hyperactivity disorder (ADHD) compound from New River Pharmaceuticals. Under the non-binding agreement, signed Friday, the companies will work to develop the compound known as NRP104 that is currently in advanced clinical trials in the U.S. New River said it expects the treatment to reach the U.S. market by 2006.
Yahoo News